Skip to content
Biotechnology

With an Eye on the Future, Biolog Launches Odin

Biolog, Inc. 2 mins read

HAYWARD, CA / ACCESSWIRE / June 15, 2023 / Biolog, Inc., a leading provider of microbial polyphasic analysis, today announced the launch of the Odin™ system, an all-in-one cellular phenotyping and microbial identification platform. Odin is compatible with all Biolog assays and is available now.

Until today, Biolog's OmniLog® platform was the gold standard for researchers who want actionable insights on microbial metabolic phenotypes. Odin now builds on that foundation while maintaining the core capabilities to incubate, analyze, and compare thousands of microbial and mammalian growth conditions in a single experiment, and to identify aerobic bacteria by its metabolic fingerprint.

Odin changes up the detection method and uses Optical Density (OD), which enables a critical additional modality to measure cell growth. Now on a single platform, researchers can distinguish the effect of a substrate on growth (by OD) and by respiration using our proprietary dye, now an absorbance-based measurement. With the additional Odin capabilities, researchers can now decouple a microbe's respiration rate from its division rate and more fully understand the metabolic output of a cell. With a fully loaded system, Odin records the OD for all conditions for up to 50 plates at a time, measuring the kinetics of cell growth and respiration for thousands of conditions in parallel.

Odin also has broader identification capabilities, including anaerobes, yeast, and filamentous fungi. All told, Odin can identify thousands of microbes, allowing researchers to classify unknown organisms and phenotype them on the same platform.

"We heard from our customers the need to directly measure growth. In a short time, we brought in additional scientific expertise, and built a product development engine. The customer-focused mindset and our dedicated teams have enabled us to quickly meet the needs of our customers," said Robert Wicke, CEO of Biolog.

"Understanding how microbes respond to their environment and food sources is the major economic driver in sustainable agriculture, bioprocessing and synthetic biology, to name just a few areas. We are enthusiastic about the foundation that Odin creates for Biolog and our customers," said Mr. Wicke.

About Biolog

Biolog has the tools, services, and support to provide the microbial phenotypic characterization and polyphasic identification capabilities required to produce functionally relevant insights. Our products and services enable characterization of microbial and mammalian cells as well as identification of thousands of species of bacteria, yeast, and fungi. Learn more at www.biolog.com.

Contact Information:

John Proctor, Ph.D.
CCO
[email protected]
(408)306-0414

SOURCE: Biolog Inc.

.


View source version on accesswire.com:
https://www.accesswire.com/761372/With-an-Eye-on-the-Future-Biolog-Launches-Odin

More from this category

  • Biotechnology
  • 12/12/2025
  • 11:40
4DMedical Limited (ASX:4DX)

4DMedical secures $30.2 million with options underwrite

Highlights• $30.2 million in funding secured by entering into an underwriting agreement that ensures the exercise of all the 4DXO listed options• Additional funding results in a proforma cash balance as at 30 September 2025 of $63.7 million • 4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning CY26 as a transformational year Melbourne, Australia, 12 December 2025: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) today announces it has entered into an option underwriting agreement (Underwriting Agreement) with Bell Potter Securities Limited (Underwriter) to fully underwrite the exercise of the 4DXO listed options on issue,…

  • Biotechnology
  • 12/12/2025
  • 10:58
EBR Systems, Inc. (ASX:EBR)

First implant in the Totally Leadless CRT (TLC-AU) Study

Key Highlights • First patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study by Dr Paul Gould from the Princess Alexandra Hospital, Brisbane • TLC-AU is a feasibility study into using the WiSE® System alongside a leadless pacemaker to achieve totally leadless CRT • The study represents a significant strategic milestone as EBR evaluates WiSE as a potential first-line therapy for treating newly diagnosed heart failure patients • TLC-AU could meaningfully expand EBR’s addressable market Sunnyvale, California; 12 December 2025: EBR Systems, Inc., developer of the world’s only wireless cardiac pacing device for heart failure, announces the first…

  • Biotechnology
  • 10/12/2025
  • 10:19
OncoSil Medical Limited (ASX:OSL)

First OncoSil treatment in United Kingdom

Sydney, Australia – 10 December 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the first commercial patient treatment in the UK using the OncoSil™ device. The successful treatment was performed on 9 December 2025 at Southampton General Hospital (University Hospital SouthamptonNHS Foundation Trust), a recognised centre of excellence in oncology. Following the hospital’s participation in the TRIPP-FFX clinical study, this significant milestone marks the transition from clinical trial involvement to the commencement of OncoSil’s commercial operations…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.